Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RESEARCH TOOLSreports
RANI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.03 - $8.75
Previous CloseN/A
Volume228.85K
Average Volume (3M)179.01K
Market Cap
$68.40M
Enterprise Value$47.82M
Total Cash (Recent Filing)$6.36M
Total Debt (Recent Filing)$30.10M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
May 07, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding33,509,827
10 Day Avg. Volume219,688
30 Day Avg. Volume179,007
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-58.17
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$10.00Price Target Upside740.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Rani Therapeutics Holdings News
PremiumCompany Announcements
Rani Therapeutics Earnings Call: Tech Gains Amid Financial Strains
PremiumCompany Announcements
Rani Therapeutics Reports 2024 Financial Results and Updates---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe initiation of a Phase 1 trial for RT-114 in obesity, utilizing innovative RaniPill capsule technology, represents a significant development step.
Financial StabilityRani has a cash runway expected to last into 3Q25 without needing additional funding, which suggests financial stability.
Market PotentialThe obesity market opportunity is large (projected to eclipse $100B by 2030), so there is a sizeable opportunity for RT-114 as a more tolerable, orally administered Tx option with a biologic payload.
Bears Say
Clinical RisksRisks include, but are not limited to: negative Phase 2 data; negative clinical readouts with other candidates; failure to achieve approvals for key pipeline projects; possible partnership risk; slower-than-projected market uptake.
Regulatory ChallengesRisks include potential negative Phase 2 data and failure to achieve approvals for key pipeline projects.
---
Options Prices
Currently, No data available
---
Ownership Overview
29.74% Insiders
2.75% Mutual Funds
5.81% Other Institutional Investors
59.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Rani Therapeutics Holdings
Desktop Users
Mobile Users
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $1.03 and its highest was $8.75 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Rani Therapeutics Holdings’s market cap is $68.40M.
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is May 07, 2025 which is in 22 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Rani Therapeutics Holdings released its earnings results on Mar 31, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.267 by -$0.003.
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate is -0.27.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 33,509,827 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Rani Therapeutics Holdings reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.267. Following the earnings report the stock price went down -2.381%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
---
Rani Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (740.34% Upside)
$10.00 (740.34% Upside)
Insider Transactions
Bought Shares
Worth $30.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.37%
12-Months-Change
Fundamentals
Return on Equity
-404.07%
Trailing 12-Months
Asset Growth
-36.75%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings (RANI) is a healthcare company focused on developing innovative oral biologics utilizing its proprietary RaniPill technology. The company operates within the biotechnology and pharmaceutical sectors, offering a unique solution for the oral delivery of biologics, which are traditionally administered via injection. Rani's core product, the RaniPill capsule, is designed to deliver large-molecule drugs through the gastrointestinal tract, thereby improving patient compliance and expanding the potential market for biologic therapies.
---
RANI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.Read More>---
RANI Stock 12 Month Forecast
Average Price Target
$10.00
▲(740.34% Upside)
Technical Analysis
Verastem
―
Arcturus Therapeutics
―
Oramed Pharm
―
XTL Biopharmaceuticals Ltd. Sponsored ADR
―
PAVmed
―
Best Analysts Covering RANI
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-30.98%
reiterated a buy rating 15 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -30.98% per trade.
---